Ferry J A, Linggood R M, Convery K M, Efird J T, Eliseo R, Harris N L
Department of Pathology, Massachusetts General Hospital, Boston 02114.
Cancer. 1993 Jan 15;71(2):457-63. doi: 10.1002/1097-0142(19930115)71:2<457::aid-cncr2820710229>3.0.co;2-u.
The prognostic significance of the cellular composition of the nodules of Hodgkin disease, nodular sclerosis type (HDNS), is controversial.
Tumors from 79 patients with HDNS, who had a median follow-up time of 9.3 years, were studied.
Based on British National Lymphoma Investigation criteria, 58 cases were classified as NSI (low-grade) and 21 as NSII (high-grade). The study included 24 male and 55 female patients, aged 10-57 years (mean, 27 years), who presented with Stage I (13 patients [12A, 1B]), Stage II (45 patients [40A, 5B]), or Stage III (21 patients [16A, 5B]) disease. Fifty-three patients had no relapse, 4 died of other causes, and 49 are in complete clinical remission. Twenty-six patients had progression of disease during therapy or relapsed and 17 were successfully salvaged. Overall length of survival was significantly shorter with NSII (P = 0.0001), extensive necrosis (P = 0.0034), high stage (P = 0.0058), and B symptoms (P = 0.030). Multivariate analysis showed that grade had the strongest effect on overall survival (P = 0.0042; hazard ratio = 10.19). The 5-year survival was 100% for NSI patients and 75% for NSII patients. Only B symptoms were significantly associated with risk of relapse after initial therapy (P = 0.030). For patients who relapsed, only histologic grade predicted subsequent disease-free survival (P = 0.0023; hazard ratio = 26.5). Five-year disease-free survival after first relapse was 94% for NSI patients and 11% for NSII patients.
Patients with NSI disease who relapse have a more successful salvage and longer period of survival than do those with NSII disease. Histologic subclassification of HDNS appears clinically relevant, and consideration of histologic subtype may be important when planning therapy.
霍奇金淋巴瘤结节硬化型(HDNS)结节的细胞组成的预后意义存在争议。
对79例HDNS患者的肿瘤进行研究,这些患者的中位随访时间为9.3年。
根据英国国家淋巴瘤研究标准,58例被分类为NSI(低级别),21例为NSII(高级别)。该研究包括24例男性和55例女性患者,年龄在10至57岁之间(平均27岁),呈现I期(13例患者[12A,1B])、II期(45例患者[40A,5B])或III期(21例患者[16A,5B])疾病。53例患者无复发,4例死于其他原因,49例处于完全临床缓解状态。26例患者在治疗期间疾病进展或复发,17例成功挽救。NSII(P = 0.0001)、广泛坏死(P = 0.0034)、高分期(P = 0.0058)和B症状(P = 0.030)患者的总生存时间显著缩短。多因素分析显示,分级对总生存的影响最强(P = 0.0042;风险比 = 10.19)。NSI患者的5年生存率为100%,NSII患者为75%。只有B症状与初始治疗后复发风险显著相关(P = 0.030)。对于复发患者,只有组织学分级可预测随后的无病生存(P = 0.0023;风险比 = 26.5)。首次复发后NSI患者的5年无病生存率为94%,NSII患者为11%。
复发的NSI疾病患者比NSII疾病患者有更成功的挽救治疗和更长的生存时间。HDNS的组织学亚分类在临床上似乎具有相关性,在规划治疗时考虑组织学亚型可能很重要。